{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:27:35Z","timestamp":1788532055898,"version":"build-2803163510"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:p>\n                    HS626, a newly approved infliximab biosimilar in China (2021), initially lacked approval for treating inflammatory bowel disease (IBD). This study aimed to evaluate the short-term efficacy and safety of HS626 in IBD inducing remission. A retrospective study (Jan 2022\u2013Apr 2024) evaluated HS626 in Crohn\u2019s disease (CD) and ulcerative colitis (UC). Disease activity was assessed using the Crohn\u2019s disease activity index and simplified endoscopic score for Crohn\u2019s disease (SES-CD) in CD patients, and the ulcerative colitis endoscopic index of severity, Mayo score, and endoscopic severity in UC patients. Blood samples were collected at weeks 0, 2, 6, and 14 to measure hemoglobin, leukocytes, platelets, albumin, C-reactive protein, and red blood cell count. Paired\n                    <jats:italic toggle=\"yes\">t<\/jats:italic>\n                    -tests\/Wilcoxon tests were used. Adverse reactions were assessed. In this study, 24 patients (11 UC, 13 CD) were enrolled, 21 patients (10 UC, 11 CD) with endoscopy data at weeks 0, 14 were enrolled. Clinical response rates were 81.8%(9\/11) in UC and 69.2%(9\/13) in CD. Clinical remission rates were 9.1%(1\/11) in UC and 76.9% (10\/13) in CD. Atopic dermatitis occurred in 1 patient (sole adverse reaction). HS626 effectively induces remission in IBD patients with a favorable short-term safety profile.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048853","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:02:12Z","timestamp":1778896932000},"page":"e48853","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Short-term efficacy and safety of infliximab biosimilar (HS626) in inducing remission of inflammatory bowel disease: A real-world single-center study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0509-7186","authenticated-orcid":false,"given":"Yun-si","family":"Huang","sequence":"first","affiliation":[{"name":"Guangxi University of Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-ping","family":"Lai","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Nong","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5718-3595","authenticated-orcid":false,"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Guangxi University of Chinese Medicine, Nanning, China"},{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China"},{"name":"Wuxi Traditional Chinese Medicine Hospital, Wuxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-yao","family":"Chen","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-bin","family":"Zeng","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-ping","family":"Huang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-yuan","family":"Lin","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260904","doi-asserted-by":"crossref","first-page":"23","DOI":"10.34172\/aim.2023.04","article-title":"Economic burden of inflammatory bowel disease in Shiraz, Iran.","volume":"26","author":"Rahmati","year":"2023","journal-title":"Arch Iran Med"},{"key":"R2-20260904","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2147\/JIR.S353038","article-title":"Immunology of inflammatory bowel disease: molecular mechanisms and therapeutics.","volume":"15","author":"Lu","year":"2022","journal-title":"J Inflamm Res"},{"key":"R3-20260904","first-page":"549","article-title":"Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience.","volume":"36","author":"Jeffrey","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"R4-20260904","doi-asserted-by":"crossref","first-page":"e39476","DOI":"10.1097\/MD.0000000000039476","article-title":"Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-na\u00efve patients with inflammatory bowel disease in the Veterans Health Administration.","volume":"103","author":"Patel","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"R5-20260904","doi-asserted-by":"crossref","first-page":"430","DOI":"10.5009\/gnl220005","article-title":"Early infliximab trough levels predict the long-term efficacy of infliximab in a randomized controlled trial in patients with active Crohn\u2019s disease comparing, between CT-P13 and originator infliximab.","volume":"17","author":"Park","year":"2023","journal-title":"Gut Liver"},{"key":"R6-20260904","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40259-020-00438-7","article-title":"Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: exploratory analyses from the NOR-SWITCH main and extension trials.","volume":"34","author":"J\u00f8rgensen","year":"2020","journal-title":"BioDrugs"},{"key":"R7-20260904","doi-asserted-by":"crossref","first-page":"2040622319838443","DOI":"10.1177\/2040622319838443","article-title":"Infliximab in inflammatory bowel disease.","volume":"10","author":"Papamichael","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"R8-20260904","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14712598.2017.1363885","article-title":"Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn\u2019s disease and ulcerative colitis \u2013 experiences from a single center.","volume":"2017","author":"Farkas","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"R9-20260904","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"R10-20260904","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/1751-2980.12994","article-title":"Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing).","volume":"22","year":"2021","journal-title":"J Dig Dis"},{"key":"R11-20260904","doi-asserted-by":"crossref","first-page":"503","DOI":"10.55489\/njcm.150620243815","article-title":"Sample size estimation in clinical trials.","volume":"15","author":"Patel","year":"2024","journal-title":"Natl J Community Med"},{"key":"R12-20260904","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"R13-20260904","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/gutjnl-2011-300486","article-title":"Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).","volume":"61","author":"Travis","year":"2012","journal-title":"Gut"},{"key":"R14-20260904","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study.","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"R15-20260904","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD.","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"R16-20260904","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"R17-20260904","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12664-022-01252-5","article-title":"Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: a real-world cohort analysis.","volume":"41","author":"Kumar","year":"2022","journal-title":"Indian J Gastroenterol"},{"key":"R18-20260904","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/jgh.14645","article-title":"Long\u2010term efficacy and safety of CT\u2010P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study.","volume":"34","author":"Kim","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"R19-20260904","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1097\/MIB.0000000000001237","article-title":"Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort: inflammatory bowel diseases.","volume":"23","author":"Gonczi","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R20-20260904","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1136\/gutjnl-2023-329964","article-title":"Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing.","volume":"72","author":"Neurath","year":"2023","journal-title":"Gut"},{"key":"R21-20260904","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/ibd\/izae159","article-title":"Mucosal and transmural healing and long-term outcomes in Crohn\u2019s disease.","volume":"31","author":"Sands","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"R22-20260904","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","article-title":"Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis.","volume":"14","author":"Shah","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R23-20260904","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-016-0676-y","article-title":"Mucosal healing in ulcerative colitis: a comprehensive review.","volume":"77","author":"Boal Carvalho","year":"2017","journal-title":"Drugs"},{"key":"R24-20260904","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/apt.15870","article-title":"Serum oncostatin M at baseline predicts mucosal healing in Crohn\u2019s disease patients treated with infliximab.","volume":"52","author":"Bertani","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-20260904","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5217\/ir.2019.00030","article-title":"Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice.","volume":"17","author":"Nakagawa","year":"2019","journal-title":"Intest Res"},{"key":"R26-20260904","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","article-title":"Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, Nationwide Cohort.","volume":"10","author":"Gecse","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R27-20260904","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.3748\/wjg.v24.i46.5288","article-title":"Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.","volume":"24","author":"Guerra Veloz","year":"2018","journal-title":"World J Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:02:50Z","timestamp":1788530570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":27,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048853","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"2025-09-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}